Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

Laminar Pharma abre una nueva ronda de financiación de ocho millones

by Laminar Pharma

5 months ago
LAM 561, Laminar Pharma

El objetivo es acabar de sufragar el ensayo clínico de su fármaco contra el cáncer de cerebro LAM 561 y «tener fuerza financiera a la hora de negociar con las farmacéuticas» para lanzar el fárm...

ZeClinics, Celtarys Research y la Universidad de Santiago se unen bajo el paraguas de la AEI de AseBio para desarrollar nuevos fármacos para el tratamiento del Parkinson

by Asebio

5 months ago
Celtarys Research, ZeClinics, Parkinson

El proyecto aúna las capacidades de validación de dianas y cribado de fármacos in vivo de ZeClinics, el conocimiento científico en diseño y síntesis de herramientas fluorescentes de Celtarys Res...

Almirall receives European Commission approval of EBGLYSS® for atopic dermatitis

by CataloniaBio

5 months ago
lebrikizumab, atopic dermatitis (AD), Almirall, EBGLYSS®

It has been announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a bodyweight of at least 4...

The DermoCosmetic Evaluation Service of the CSIC obtains the Good Laboratory Practices certificate in percutaneous absorption

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

5 months ago
biocides, Good Laboratory Practices (GLP) certification, DermoCosmetic Evaluation Service

The DermoCosmetic Evaluation Service of the Institute for Advanced Chemistry of Catalonia (IQAC) from the Spanish National Research Council (CSIC) has obtained the Good Laboratory Practices (GLP) cert...

Glycobasque 6: A successful convergence of leading minds in glycoscience

by CIC bioGUNE

5 months ago
Glycobasque 6, glycoscience

Professionals, experts, and researchers across diverse glycoscience disciplines, encompassing glycobiology, immunology, and carbohydrate chemistry, converge at the 6th edition of Glycobasque.

Certest completes the expansion of its new facilities after investing €22 million

by Certest

5 months ago
Certest

Certest, a pioneering Aragonese biotechnology company in the development and manufacturing of in vitro diagnostic tests for infectious diseases, is advancing in its expansion with the aim of entering ...

Desarrollan un nuevo antiinflamatorio no esteroideo y regulador inmunitario que puede sustituir a los corticoides

by CSIC - Centro Superior de Investigaciones Científicas

5 months ago
AG5, citoquinas

El compuesto, creado por un equipo liderado por el CSIC y la UPV, es capaz de inhibir la tormenta de citoquinas asociada a la inflamación grave conservando la inmunidad innata

ALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys

by Asabys Partners

5 months ago
ALLOX, Sabadell Asabys II, Asabys Partners, CRG, allosteric sites

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the succes...

ORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S

by Oryzon Genomics

5 months ago
ORY-4001, amyotrophic lateral sclerosis (ALS), HDAC6, ALS Association, Oryzon

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selectiv...

Researchers from CIC bioGUNE develop a strategy capable of identifying the cellular components on which the E3 ubiquitin ligase enzymes act

by CIC bioGUNE

5 months ago
E3 ubiquitin ligase enzymes, Targeted Protein Degradation (TPD)

It has beed used innovative strategies to redirect cellular degradation and thus eliminate proteins that cause various diseases.

IBEC engages in two public-private partnerships for biomedical breakthroughs

by IBEC - Institut de Bioenginyeria de Catalunya

5 months ago
IBEC, Vitala Technologies

Initiatives seek to advance remote health monitoring, create an oral drug for Inflammatory Bowel Disease, and enhance 13C magnetic resonance imaging for therapeutic research. Leveraging cutting-edge t...

IMIDomics expands long-standing partnership with Bristol Myers Squibb to advance immune-mediated inflammatory disease treatment research and development

by CataloniaBio

5 months ago
Immune-Mediated Inflammatory Diseases (IMIDs), Bristol Myers Squibb, IMIDomics

This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.